Molecular Subtyping and Therapeutic Targeting of <scp>IFNG</scp>‐Driven Immunogenic Cell Death in Lung Adenocarcinoma
Identification of novel ICD-related molecular subtypes holds promise for guiding personalized therapies, assessing prognosis, and predicting immunotherapy efficacy in LUAD. IFNG emerges as a potential prognostic biomarker and therapeutic target, influencing both the tumor microenvironment and angiogenesis. These findings offer new insights into therapeutic strategies targeting IFNG-mediated pathways in LUAD.
Authors
- Ming Cheng (ORCID: https://orcid.org/0000-0002-1742-7022)
- Xiaoran Duan (ORCID: https://orcid.org/0000-0001-8533-7750)
- Lifeng Li (ORCID: https://orcid.org/0000-0002-9813-5688)
- Jie Zhao (ORCID: https://orcid.org/0000-0003-1168-8384)
- Xuefeng Lv
- Baojun Wang (ORCID: https://orcid.org/0000-0002-4858-8937)
- Chengxin Chen (ORCID: https://orcid.org/0000-0003-4510-3313)
- Mengle Peng (ORCID: https://orcid.org/0000-0001-8693-6923)
- Zhirui Fan (ORCID: https://orcid.org/0000-0002-0389-5271)
- Ruyue Xue (ORCID: https://orcid.org/0000-0001-9028-7794)
- Yaqi Yang (ORCID: https://orcid.org/0000-0001-9460-6860)
- Li Zhu (ORCID: https://orcid.org/0000-0001-5249-6536)
Institutions
- Zhengzhou University (CN)
- Henan Provincial People's Hospital (CN)
- Zhengzhou Central Hospital (CN)
- Third Affiliated Hospital of Zhengzhou University (CN)
- Zhengzhou People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Huanghe Science and Technology College (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70678
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China